|This message contains images. If you don't see images, click here to view.|
Advertise in this news brief.
Academia, Government, or Industry? Which One is Right for You?
Although competition for life sciences jobs has become fierce, most Ph.D. life scientists will ultimately find jobs in academia, government, or the pharmaceutical or biotechnologies industries. While these jobs share many things in common, there are differences in compensation and benefits, job security, workplace culture, and career advancement.
Frequently, life scientists choose career paths without knowing much about them. Therefore, it may be informative to better understand the similarities and differences between academic, government, and industry jobs before taking the career plunge.
Read more on the Career Success webpage of the AAPS Career Center.
For a complete list of job postings, click here.
Have a job to post? Click here.
PHARMACEUTICAL CAREER NEWS
Translational Cell Biology Careers Turn On Technological Savvy
Translational cell biologists pursue research questions that have a direct impact on treating human diseases. But to build a successful career, young cell biologists must also be well versed in technologies, such as those for advanced imaging, data mining, and biophysics, to push their research ahead. These cell biologists must embrace skills usually found in other departments — such as programming, performing heavy-duty statistical analysis, and even building devices from scratch in the machine shop.
A Job Seekers Guide To Understanding the Interviewers Perspective
A medical sales resume can tell a recruiter or hiring manager something about a candidate’s qualifications, but hiring managers generally rely on the interview itself to get to know the candidate and see if they’ll be a good fit.
According to MedReps’ recent Guide To Effective Interviewing, 46 percent of new hires fail within 18 months of employment and only 19 percent achieve unequivocal success.
Transparency in Clinical Trials: Why the Industry Isn't Measuring Up
A recent study conducted by Bioethics International — a not-for-profit organization that keeps tabs on the way pharmaceutical companies develop and market drugs in order to determine the ethics behind these practices — found that many large pharmaceutical companies failed to achieve transparency in their clinical trial results. The main take-home result of the study, was that only two out of every three clinical trials in 2012 — the results of which were used to support new drug approval applications — were ever disclosed to the proper authorities.
FDA Releases Guidance on Communication with the Agency
FDA released draft guidance on Dec. 4, 2015 on the agency’s recommendations for best practices in communication between investigational new drug application (IND) sponsors and FDA during drug development. The guidance provides FDA’s expectations for methods of communication and timing of FDA responses to IND sponsor inquiries. It also details the types of advice and interactions that are appropriate between IND sponsors and FDA review teams.
Troubles Ahead for the Pharmaceutical Industry
Give Pfizer credit for doing what no one thought could be done: It has united the fractured landscape of American politics. There was not a hint of disagreement among the presidential candidates — who can agree on nothing else — in responding to the company’s decision to move its tax domicile to Ireland. Donald Trump called it “disgusting.” Bernie Sanders deemed it “disastrous.” Hillary Clinton said the company is leaving “U.S. taxpayers holding the bag.”
US Officials Seek Business Help To Sell Pacific Trade Pact
U.S. officials and lawmakers urged business leaders to get behind a Pacific trade pact as they vowed an all-out effort next year to get the deal through the U.S. Congress.
Negotiators from 12 countries sealed the Trans-Pacific Partnership trade pact, a key plank of U.S. President Barack Obama's outreach to Asia, in October, but it has so far won a mixed reception in Congress.
Rare Diseases: The Pharmaceutical Landscape and Opportunity Analysis
The service oriented and dynamic nature of the healthcare industry has led to the discovery of a plethora of treatment options for a wide range of ailments. However, there are certain diseases, termed as rare, that continue to remain untreated and neglected. Rare / orphan diseases, as the name suggests, are those diseases which are relatively infrequent in occurrence. Many orphan diseases are life-threatening and progressive in nature. Absence of potential treatment regimes catering to these diseases is a big unmet need in the market.
Nine Prep Tips To Ace Your Job Interview
By Hank Boyer
Congratulations! You just got a call from the employer whose job posting seemed like a perfect fit, and they want you to interview next Wednesday. You've got a little less than a week to prepare to ace your interview.
French Pharmaceutical Firm Servier Plans to Cut 610 Jobs
Drug Discovery & Development
Privately-owned French pharmaceutical company Servier said it planned to cut 610 jobs and would reorganise its sales network due to competitive pressures and a tougher regulatory environment.
Creating Habits For Success: 5 Strategies For Staying On Track
By Michelle LaBrosse
What habits do you need to develop to become a more effective project manager? Maybe you need to get more organized with your paperwork, or change how you spend your time each day to stay on track with your projects, or shift how you respond to stressful situations.
Regardless of the kind of habit you're trying to form, you might find that changing your day-to-day behavior is more challenging that you expected. It may be the case that you've tried before to adopt this new habit, but somehow got derailed from your goal.
A Record-Breaking Pharmaceutical Merger
What do you get when you mix Viagra and Botox? We are about to find out, at least with respect to financial impact. With respect to the products, feel free to make your own punchline — we're not going there.
Pfizer, the pharmaceutical giant that manufactures Viagra and many other common medications such as Lipitor, Advil, and Neosporin, recently agreed to a record-breaking $160 billion merger with Allergan, the maker of Botox.
AAPS Career Services
Colby Horton, Vice President of Publishing, MultiBriefs, 469.420.2601
Download media kit
Jessica Taylor, Medical Editor, MultiBriefs, 202.684.7169
Be sure to add us to your address book or safe sender list so our emails get to your inbox. Learn how.
This edition of the AAPS Pharmaceutical Career News was sent to ##Email##. To unsubscribe, click here. Did someone forward this edition to you? Subscribe here -- it's free!
Nov. 13, 2015
Oct. 9, 2015
Sept. 11, 2015
Aug. 28, 2015
7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063